India’s Shantha Said To Be Acquisition Target Of GSK, Sanofi
This article was originally published in PharmAsia News
Two multinational drug makers are reported to be eyeing India's Shantha Biotech as an acquisition. Sources identified the two suitors as U.K.-based GlaxoSmithKline and French drug maker Sanofi-Aventis. Both firms are said to be holding separate talks with the French majority owner, Merieux Alliance, with GSK considered the front-runner. One source said Merieux seeks to sell its entire 80 percent stake in Shantha, valued at more than $196 million. GSK and Sanofi-Aventis said the reports were speculative and Merieux would not comment. (Click here for more
You may also be interested in...
Cipla is celebrating an “important milestone” for the company after the successful completion of a Phase III clinical trial comparing its proposed Advair generic with GSK’s brand in the US. Management has cautioned that approval will be a way off yet, however.
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.